Rubratin
Alternative Names: N CWS; Nocardia CWS; RubratineLatest Information Update: 23 Jun 1998
At a glance
- Originator Fujisawa
- Developer ASTA Medica [CEASED]; Fujisawa
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 30 May 1995 Discontinued-preregistration for Cancer in Japan (Unknown route)
- 30 May 1995 Discontinued-Unspecified phase in Cancer in Germany (Unknown route)